Skip to main content

Table 1 Neuroblastoma patient’s dataset

From: Artificial neural network classifier predicts neuroblastoma patients’ outcome

Patients’ characteristics

Training seta

Test seta

Age at diagnosisb

  < 1 year

50 (50 %)

36 (44 %)

  ≥ 1 year

50 (50 %)

46 (56 %)

INSS stagec

 1,2,3,4s

67 (67 %)

49 (60 %)

 4

33 (33 %)

33 (40 %)

MYCN statusd

 normal

84 (84 %)

68 (83 %)

 amplified

16 (16 %)

14 (17 %)

Outcomee

 Good

72 (72 %)

59 (72 %)

 Poor

28 (28 %)

23 (28 %)

  1. aThe 182 patients’ dataset is split into two groups of 100 and 82 patients representing the training and test set, respectively
  2. The total number of patients and the relative percentage in each subdivision is shown
  3. bAge at diagnosis is defined as the patient’s age before or after 1 year
  4. cINSS stage is defined according to the International Neuroblasma Staging System (INSS) [2]
  5. INSS divided tumors into 5 stages (1,2,3,4,4s)
  6. Stage 1 indicates localised tumour with incomplete gross excision; representative ipsilateral non-adherent lymph nodes negative for tumour microscopically. Stage 2 indicates localised tumour with or without complete gross excision, with ipsilateral non-adherent lymph nodes positive for tumour. Enlarged contralateral lymph nodes should be negative microscopically. Stage 3 indicates unresectable unilateral tumour infiltrating across the midline, with or without regional lymph node involvement; or localised unilateral tumour with contralateral regional lymph node involvement; or midline tumour with bilateral extension by infiltration (unresectable) or by lymph node involvement. Stage 4 indicates any primary tumour with dissemination to distant lymph nodes, bone, bone marrow, liver, skin, or other organs (except as defined by stage 4s). Stage 4s indicates localised primary tumour in infants younger than 1 year with dissemination limited to skin, liver, or bone marrow
  7. dThe status of the N-myc proto-oncogene is defined as amplified or normal according to the copy number of the gene on chromosome 2
  8. eGood and poor outcome were defined as patient’s status (alive or dead) 5 years after diagnosis
Back to article page

BMC Bioinformatics

ISSN: 1471-2105

Contact us